产品/疗法

低磷血症作为 CAR-T 细胞接受者免疫效应细胞相关神经毒性综合征的标志物

Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients.

源自肿瘤微环境的无细胞 RNA 特征预测大 B 细胞淋巴瘤 CAR-T 疗法的结局

Cell-free RNA Signatures Derived from the Tumor Microenvironment Predict Outcomes of CAR-T Therapy in Large B Cell Lymphoma.

细胞治疗用于弥漫大 B 细胞淋巴瘤：I 期临床试验（University Health）

Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta

这是一项 I 期注册临床试验，评估细胞治疗用于弥漫大 B 细胞淋巴瘤的安全性、可行性及初步疗效。当前状态：招募中。计划入组 40 例。试验地点：其他 · 多伦多（共 1 个中心）。登记号：NCT05950802。

协变量对非霍奇金淋巴瘤患者 Axicabtagene Ciloleucel（axi-cel）动力学的影响研究

Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin's Lymphoma.

本研究中考虑的任何协变量均未发现能显著且实质性地预测 axi-cel 的暴露特征。托珠单抗和类固醇的使用与最大浓度相关，但它们是被动用于治疗与较高最大浓度相关的毒性反应。进一步的 CAR-T 动力学分析应考虑其他因素，以解释观察到的细胞动力学变异性，或帮助建立剂量-暴露关系。

伴假性进展和巨细胞病毒感染的复发性滤泡性淋巴瘤对新型抗 CD19 CAR-T 治疗的快速应答：病例报告

Rapid response in relapsed follicular lymphoma to novel anti-CD19 CAR-T therapy with pseudo-progression and cytomegalovirus infection: A case report.

CD19 CAR-T 淋巴细胞对人 B 细胞来源血液系统恶性肿瘤的免疫治疗

Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes.

监测 CAR-T 细胞治疗疗效与应答的液体活检方法

Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy.

在同时检测患者外周血中的 CAR-T 细胞和 B 细胞恶性肿瘤时，HDSCA-HemeCAR 工作流程可考虑用于风险监测和患者管理。

比较共刺激结构域对已获批 CD19 CAR 功能影响的复杂性

Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality.

罕见病基因治疗的临床应用：综述

Clinical applications of gene therapy for rare diseases: A review.

CD19 CAR 抗原结合机制与亲和力调节

CD19 CAR antigen engagement mechanisms and affinity tuning.

通过分子建模、对接和动力学方法对 CAR-T 细胞治疗血液肿瘤中一种新蛋白的计算机模拟分析

In silico analysis of a novel protein in CAR T- cell therapy for the treatment of hematologic cancer through molecular modelling, docking, and dynamic

癌症免疫与基因治疗的新兴前沿

Emerging frontiers in immuno- and gene therapy for cancer.

CAR-T 治疗在血液系统恶性肿瘤中的历程

The journey of CAR-T therapy in hematological malignancies.

B 细胞淋巴瘤的新二线治疗

New Second-Line Treatment for B-Cell Lymphoma.

CAR-T 细胞治疗产品的免疫原性：证据、机制与减轻策略

Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation.

生产工艺对 CAR-T 细胞功能的影响

Impact of Manufacturing Procedures on CAR T Cell Functionality.

CAR-T 细胞/-NK 细胞在肿瘤免疫治疗中的作用及 MSC 增强其疗效的潜力：综述

CAR-T Cells/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review.

用于治疗复发/难治性非霍奇金淋巴瘤的持久性 4-1BB 基 CD19 CAR-T 细胞

A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma.

这些结果证明了基于 4-1BB 的 CD19 CAR-T 产品 IM19 的安全性和持久疗效，其有望用于进一步开发和临床研究。

抗 CD19 CAR-T 细胞输注的住院给法国国家医疗保险带来多少费用

How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?

利用 CRISPR/Cas9 技术强化 CAR-T 细胞治疗应用

Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.